Investors in Iot

We invest in European early stage biotech opportunities with a clear path to the clinic, whether single-asset or platform. FORTY51 Ventures is the first institutional investor in your biotech company. FORTY51 Ventures Is A Biotech Venture Creator Company Building. We invest in European early stage biotech opportunities with a clear path to the clinic, whether single-asset or platform.

KOOPEO Ventures is Prague-based investment company that makes pre-seed and seed stage investments in CEE region.They seek out emerging projects with high growth potential in industries such as E-commerce, Mobile, Internet, Affiliate Marketing, and Fintech.

We, at HCVC, are a venture capital firm that helps fearless founders tackle hard problems with our capital, resources, and collaboration.

Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target the world's most urgent medical needs. Ω is the last letter of the Greek alphabet. Our investment process starts by focusing on the end goal – delivering impactful medicines to patients. We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others. Early seed or late stage public financing. Large markets or rare diseases. Established targets or novel technologies.

Novo Holdings is a holding company specializing in life science investor with a focus on creating long-term value.Novo Holdings is a world-leading life science, improving health, sustainability, and generating attractive returns. As the holding and investment company of the Novo Nordisk Foundation,

Lundbeckfonden Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by Lundbeck Foundation.The Lundbeck Foundation is a commercial foundation with a strong purpose:We create powerful ripple effects that bring discoveries to lives through investing actively in business and science at the frontiers of their fields.

Nordic Alpha Partners is a growth fund that invests in hard-tech companies with potential to drive global market transformations.Nordic Alpha Partners is specialized in managing the complexity of scaling industrial GreenTech, enabling visionary founders to successfully grow from local players to global market leaders.

Agronomics is an investment business specializing in environmentally sustainable opportunities within the growing food industry. They focus on supporting ventures that innovate in sustainable agriculture, alternative proteins, and other technologies that promote ecological responsibility in food production. Agronomics' investment strategy is guided by a commitment to fostering positive environmental impact while generating financial returns. By partnering with pioneering companies in the food sector, Agronomics aims to advance sustainable practices and contribute to the global shift towards more sustainable food production systems.

Esperante, a corporate venture capital firm affiliated with a global life science group, boasts leadership with deep operational expertise in the development, manufacturing, and global marketing of prescription pharmaceuticals and in vitro clinical diagnostic tests. Since its establishment in 2004, Esperante has strategically invested in 24 pharmaceutical and diagnostic companies across the US, UK, continental Europe, and Israel. Notably, the firm has achieved three successful exits: Thiakis to Wyeth/Pfizer, Pinnacle Biologics to Concordia, and Haemostatix to Ergomed. Currently, four portfolio companies are publicly listed in the US, Canada, and UK, with a focus on therapeutics in advanced clinical stages and diagnostics companies entering the European market. Esperante pursues initial investments of up to EUR 2,000,000 per venture in collaboration with other investors, aiming for exits through sales or liquidity events within a three-year timeframe.

Abingworth is a distinguished international investment firm specializing in the life sciences and healthcare sectors. Founded in 1973, we have a long-standing reputation for supporting innovative companies at various stages of development, from early-stage startups to late-stage growth enterprises. Our investment portfolio spans biotechnology, pharmaceuticals, medical devices, and healthcare services, reflecting our commitment to advancing cutting-edge technologies and treatments. With our team of seasoned professionals bringing deep industry knowledge and extensive experience, we provide strategic guidance and operational support to our portfolio companies. Our global presence, with offices in London, Menlo Park, and Boston, allows us to identify and invest in promising opportunities worldwide. Dedicated to fostering innovation and improving patient outcomes, we have successfully supported numerous companies in achieving significant milestones, demonstrating our ability to add value and drive growth.

M Ventures is the strategic corporate venture capital fund of Merck KGaA, Darmstadt, Germany. Established in 2009, it manages a fund of €600 million, investing in biotechnology and technology sectors. The fund focuses on healthcare drug development, life science tools, electronics, and frontier technology and sustainability. M Ventures aims to support visionary companies that develop innovative solutions for treating diseases, advancing scientific research, and addressing sustainability challenges. They take an active role in their portfolio companies, collaborating closely with entrepreneurs and co-investors.

Raw Ventures, we are a forward-thinking venture capital firm specializing in early-stage investments within the technology sector. Our mission at Raw Ventures is to identify and support ambitious entrepreneurs who are creating innovative solutions across diverse industries. We combine strategic capital investment with hands-on operational support, aiming to foster growth and success for our portfolio companies.